Search results for "LIPOPROTEIN"

showing 10 items of 982 documents

β-amyloid wall deposit of temporal artery in subjects with spontaneous intracerebral haemorrhage.

2018

// Antonino Tuttolomondo 1 , Rosario Maugeri 4 , Elisabetta Orlando 2 , Giulio Giannone 2 , Francesco Ciccia 3 , Aroldo Rizzo 5 , Domenico Di Raimondo 1 , Francesca Graziano 4 , Rosaria Pecoraro 1 , Carlo Maida 1 , Irene Simonetta 1 , Anna Cirrincione 1 , Francesca Portelli 2 , Francesca Corpora 1 , Domenico Gerardo Iacopino 4 and Antonio Pinto 1 1 Internal Medicine and Stroke Care Ward, Dipartimento Biomedico di Medicina Interna e Specialistica, University of Palermo, Palermo, Italy 2 Human Pathology Section, Human Pathology Section, Department of Health Sciences, University of Palermo, Palermo, Italy 3 Rheumathology Ward, Dipartimento Biomedico di Medicina Interna e Specialistica, Univers…

0301 basic medicineApolipoprotein Emedicine.medical_specialtySettore MED/09 - Medicina InternaGastroenterologysuperficial temporal artery03 medical and health sciences0302 clinical medicineβ amyloidInternal medicinemedicine.arteryBiopsymedicineβ-amyloid temporal arterymedicine.diagnostic_testbusiness.industrySettore MED/27 - Neurochirurgiaβ-amyloidintracerebral haemorrhageUniversity hospitalControl subjectsmedicine.diseaseSuperficial temporal artery030104 developmental biologyOncologyTemporal arteryCerebral amyloid angiopathybusiness030217 neurology & neurosurgeryResearch PaperCAAH
researchProduct

Unsaturated Oral Fat Load Test Improves Glycemia, Insulinemia and Oxidative Stress Status in Nondiabetic Subjects with Abdominal Obesity.

2016

Aims To evaluate the changes in glycemia, insulinemia, and oxidative stress markers during an oral fat load test in nondiabetic subjects with abdominal obesity and to analyze the association between postprandial oxidative stress markers and postprandial glucose and insulin responses. Methods We included 20 subjects with abdominal obesity (waist circumference > 102 cm for men and > 88 cm for women) and 20 healthy lean controls (waist circumference < 102 cm for men and < 88 cm for women). After 12 hours of fasting we performed a standardized fat load test (0–8 hours) with supracal® (50 g/m2). We determined metabolic parameters, oxidized and reduced glutathione, and malondialdehyde. Results In…

0301 basic medicineBlood GlucoseMalePhysiologymedicine.medical_treatmentlcsh:MedicineBiochemistryFatschemistry.chemical_compound0302 clinical medicineEndocrinologyMalondialdehydeMedicine and Health SciencesInsulinlcsh:ScienceAbdominal obesityMultidisciplinaryOrganic CompoundsMonosaccharidesMiddle AgedMalondialdehydePostprandial PeriodGlutathioneLipidsChemistryPostprandialCholesterolPhysiological ParametersObesity AbdominalPhysical SciencesFemalemedicine.symptomResearch ArticleAdultmedicine.medical_specialtyWaistAdolescentLipoproteinsCarbohydrates030209 endocrinology & metabolism03 medical and health sciencesYoung AdultInsulin resistanceInternal medicinemedicineHumansObesityAgedDiabetic EndocrinologyEndocrine Physiologybusiness.industryInsulinUnsaturated fatlcsh:RBody WeightOrganic ChemistryChemical CompoundsBiology and Life SciencesProteinsCell Biologymedicine.diseaseObesityHormonesFats UnsaturatedOxidative Stress030104 developmental biologyEndocrinologyGlucosechemistryCase-Control Studieslcsh:QInsulin ResistancebusinessPloS one
researchProduct

Low level activity thresholds for changes in NMR biomarkers and genes in high risk subjects for type 2 diabetes

2017

AbstractOur objectives were to determine if there are quantitative associations between amounts and intensities of physical activities (PA) on NMR biomarkers and changes in skeletal muscle gene expressions in subjects with high risk for type 2 diabetes (T2D) performing a 3-month PA intervention. We found that PA was associated with beneficial biomarker changes in a factor containing several VLDL and HDL subclasses and lipids in principal component analysis (P = &lt;0.01). Division of PA into quartiles demonstrated significant changes in NMR biomarkers in the 2nd - 4th quartiles compared to the 1st quartile representing PA of less than 2850 daily steps (P = 0.0036). Mediation analysis of PA-…

0301 basic medicineBlood GlucoseMaleVery low-density lipoprotein[SDV]Life Sciences [q-bio]prévention des maladieslcsh:MedicineAdipose tissueMuscle ProteinsType 2 diabetes030204 cardiovascular system & hematologyOverweight0302 clinical medicinemaladie cardiovasculairelcsh:ScienceComputingMilieux_MISCELLANEOUSBODY-WEIGHT CHANGEMultidisciplinaryMiddle AgedMagnetic Resonance Imaging[SDV] Life Sciences [q-bio]ADIPOSE-TISSUEBiomarker (medicine)SKELETAL-MUSCLEFemalemedicine.symptombiomarqueurINSULIN-RESISTANCE ATHEROSCLEROSISAutre (Sciences du Vivant)Adultmedicine.medical_specialtydiabète de type 2expression géniqueCarbohydrate metabolismALL-CAUSEArticle03 medical and health sciencesMedical researchLIPID-METABOLISMInternal medicineDiabetes mellitusmedicineAPOLIPOPROTEIN-D POLYMORPHISMHumansObesityNUCLEAR-MAGNETIC-RESONANCEMuscle SkeletalExercisebusiness.industryMORTALITYlcsh:RLipid metabolismsurpoidsLIPOPROTEIN PARTICLE-SIZEmedicine.disease030104 developmental biologyEndocrinologyPHYSICAL-ACTIVITYDiabetes Mellitus Type 2Gene Expression Regulationlcsh:QbusinessBiomarkers
researchProduct

Deregulated Lipid Sensing by Intestinal CD36 in Diet-Induced Hyperinsulinemic Obese Mouse Model

2016

International audience; The metabolic syndrome (MetS) greatly increases risk of cardiovascular disease and diabetes and is generally associated with abnormally elevated postprandial triglyceride levels. We evaluated intestinal synthesis of triglyceride-rich lipoproteins (TRL) in a mouse model of the MetS obtained by feeding a palm oil-rich high fat diet (HFD). By contrast to control mice, MetS mice secreted two populations of TRL. If the smaller size population represented 44% of total particles in the beginning of intestinal lipid absorption in MetS mice, it accounted for only 17% after 4 h due to the secretion of larger size TRL. The MetS mice displayed accentuated postprandial hypertrigl…

0301 basic medicineCD36 Antigens[SDV]Life Sciences [q-bio]lcsh:Medicine030204 cardiovascular system & hematologyLipoprotein MetabolismMice0302 clinical medicineIntestinal mucosaHyperinsulinemiaIntestinal Mucosalcsh:ScienceMetabolic Syndromeeducation.field_of_studyMultidisciplinaryIntestinal lipid absorption3. Good healthPostprandialChain Fatty-Acidslipids (amino acids peptides and proteins)Research ArticleNonfasting Triglyceridesmedicine.medical_specialtyPopulationTransportDistal IntestineBiologyDiet High-FatAbsorption03 medical and health sciencesInsulin resistanceInternal medicineHyperinsulinismmedicineAnimalsCholesterol UptakeObesityeducationSecretion[ SDV ] Life Sciences [q-bio]Insulin-Resistancelcsh:RHypertriglyceridemiaLipid metabolismmedicine.diseaseLipid MetabolismDisease Models Animal030104 developmental biologyEndocrinologyGene Expression Regulationlcsh:Q[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition
researchProduct

Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN)

2017

Background and aims: Primary dyslipidemias are a heterogeneous group of disorders characterized by abnormal levels of circulating lipoproteins. Among them, familial hypercholesterolemia is the most common lipid disorder that predisposes for premature cardiovascular disease. We set up an Italian nationwide network aimed at facilitating the clinical and genetic diagnosis of genetic dyslipidemias named LIPIGEN (LIpid TransPort Disorders Italian GEnetic Network). Methods: Observational, multicenter, retrospective and prospective study involving about 40 Italian clinical centers. Genetic testing of the appropriate candidate genes at one of six molecular diagnostic laboratories serving as nationw…

0301 basic medicineCandidate geneGenetic testingSettore MED/09 - Medicina InternaDatabases FactualDNA Mutational AnalysisDiseaseFamilial hypercholesterolemia030204 cardiovascular system & hematology0302 clinical medicineDyslipidemias; Genetic testing; National network; Internal Medicine; Cardiology and Cardiovascular MedicineRisk FactorsProspective StudiesProgram DevelopmentProspective cohort studymedicine.diagnostic_testGeneral MedicinePrognosisCholesterolPhenotypeItalyCardiology and Cardiovascular MedicineGenetic Markersmedicine.medical_specialtyNational networkDyslipidemias; Genetic testing; National networkMEDLINEHyperlipoproteinemia Type II03 medical and health sciencesDatabasesInternal medicinemedicineInternal MedicineHumansGenetic Predisposition to DiseaseFactualGenetic testingRetrospective StudiesDyslipidemiasbusiness.industrySettore MED/13 - ENDOCRINOLOGIARetrospective cohort studymedicine.diseaseAtherosclerosisDyslipidemias; Genetic testing; National network; Atherosclerosis; Cholesterol; DNA Mutational Analysis; Databases Factual; Genetic Markers; Genetic Predisposition to Disease; Humans; Hyperlipoproteinemia Type II; Italy; Phenotype; Prognosis; Program Development; Prospective Studies; Retrospective Studies; Risk Factors; Mutation; Internal Medicine; Cardiology and Cardiovascular Medicine030104 developmental biologyEndocrinologyDyslipidemiaGenetic markerMutationbusiness
researchProduct

Palmitoylethanolamide Promotes a Proresolving Macrophage Phenotype and Attenuates Atherosclerotic Plaque Formation

2018

Objective— Palmitoylethanolamide is an endogenous fatty acid mediator that is synthetized from membrane phospholipids by N -acyl phosphatidylethanolamine phospholipase D. Its biological actions are primarily mediated by PPAR-α (peroxisome proliferator-activated receptors α) and the orphan receptor GPR55. Palmitoylethanolamide exerts potent anti-inflammatory actions but its physiological role and promise as a therapeutic agent in chronic arterial inflammation, such as atherosclerosis remain unexplored. Approach and Results— First, the polarization of mouse primary macrophages towards a proinflammatory phenotype was found to reduce N -acyl phosphatidylethanolamine phospholipase D expression …

0301 basic medicineCannabinoid receptorTime FactorsMice Knockout ApoECHOLESTEROL TRANSPORTAnti-Inflammatory AgentsPhospholipaseProto-Oncogene Maschemistry.chemical_compoundCannabinoid receptor type 2Receptors CannabinoidAortachemistry.chemical_classificationMARROW-DERIVED CELLSAPOPTOTIC CELL ACCUMULATIONPlaque AtheroscleroticCell biologymacrophagesDENSITY-LIPOPROTEIN RECEPTORPhenotypeREDUCES INFLAMMATIONCB2 RECEPTOREthanolaminesFemaleCardiology and Cardiovascular MedicineSCAVENGER RECEPTORAortic DiseasesPalmitic Acidsta3111fatty acidsCell Line03 medical and health sciencesMediatorPhagocytosisPhospholipase DAnimalsHumansScavenger receptorCANNABINOID RECEPTORPhosphatidylethanolaminePalmitoylethanolamidec-Mer Tyrosine KinaseFatty acidcholesterolta3121AmidesRatsMice Inbred C57BLDisease Models Animal030104 developmental biologychemistryinflammationRECEPTOR CLASS-BatherosclerosisCONTACT ALLERGIC DERMATITISArteriosclerosis Thrombosis and Vascular Biology
researchProduct

SGLT-2 (Sodium-Glucose Cotransporter 2) Inhibition Reduces Ang II (Angiotensin II)-Induced Dissecting Abdominal Aortic Aneurysm in ApoE (Apolipoprote…

2019

Objective: Abdominal aortic aneurysm (AAA) is a pathological condition of permanent vessel dilatation that predisposes to the potentially fatal consequence of aortic rupture. SGLT-2 (sodium-glucose cotransporter 2) inhibitors have emerged as powerful pharmacological tools for type 2 diabetes mellitus treatment. Beyond their glucose-lowering effects, recent studies have shown that SGLT-2 inhibitors reduce cardiovascular events and have beneficial effects on several vascular diseases such as atherosclerosis; however, the potential effects of SGLT-2 inhibition on AAA remain unknown. This study evaluates the effect of oral chronic treatment with empagliflozin—an SGLT-2 inhibitor—on dissecting …

0301 basic medicineDissecting Abdominal Aortic AneurysmApolipoprotein EMalemedicine.medical_specialtyInflammation030204 cardiovascular system & hematologyp38 Mitogen-Activated Protein Kinases03 medical and health sciencesMice0302 clinical medicineApolipoproteins EGlucosidesInternal medicinemedicineAnimalsHumansBenzhydryl CompoundsAortic ruptureSodium-Glucose Transporter 2 InhibitorsCells CulturedNeovascularization Pathologicbusiness.industryAngiotensin IINF-kappa Bmedicine.diseaseAngiotensin IIAbdominal aortic aneurysmMatrix MetalloproteinasesMice Inbred C57BLAortic Dissection030104 developmental biologyEndocrinologySodium/Glucose Cotransporter 2Knockout mousemedicine.symptomChemokinesCardiology and Cardiovascular MedicinebusinessAortic Aneurysm AbdominalArteriosclerosis, thrombosis, and vascular biology
researchProduct

Nutraceuticals as an Important Part of Combination Therapy in Dyslipidaemia

2017

Several risk factors such as abnormality of lipid metabolism (e.g. high levels of low-density lipoprotein cholesterol (LDL-C), elevated triglycerides and low levels of high-density lipoprotein cholesterol (HDL-C)) play a central role in the aetiology of cardiovascular disease (CVD). Nutraceutical combination together with a cholesterol- lowering action, when associated with suitable lifestyle, should furnish an alternative to pharmacotherapy in patients reporting statin-intolerance and in subjects at low cardiovascular risk. The present review is focused on nutraceuticals and their synergetic combinations demonstrating a beneficial effect in the management of dyslipidaemia. Several nutraceu…

0301 basic medicineDyslipidaemiaCombination therapyLow density lipoprotein cholesterol030204 cardiovascular system & hematologyReductaseBiologyPharmacology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNutraceuticalBerberineDrug DiscoverymedicineRed yeast riceHumansEndothelial dysfunctionEndothelial dysfunctionDyslipidemiasCarotidDietary SupplementPharmacologyCholesterolLipid metabolismLipidCardiovascular riskmedicine.diseaseLipidsIntima media thickne030104 developmental biologyDyslipidemiachemistryDietary SupplementsDrug Therapy Combinationlipids (amino acids peptides and proteins)NutraceuticalHumanCurrent Pharmaceutical Design
researchProduct

Hyperalphalipoproteinemia and Beyond: The Role of HDL in Cardiovascular Diseases

2021

Hyperalphalipoproteinemia (HALP) is a lipid disorder characterized by elevated plasma high-density lipoprotein cholesterol (HDL-C) levels above the 90th percentile of the distribution of HDL-C values in the general population. Secondary non-genetic factors such as drugs, pregnancy, alcohol intake, and liver diseases might induce HDL increases. Primary forms of HALP are caused by mutations in the genes coding for cholesteryl ester transfer protein (CETP), hepatic lipase (HL), apolipoprotein C-III (apo C-III), scavenger receptor class B type I (SR-BI) and endothelial lipase (EL). However, in the last decades, genome-wide association studies (GWAS) have also suggested a polygenic inheritance o…

0301 basic medicineEndothelial lipasemedicine.medical_specialtyApolipoprotein BHDLSciencePopulationGenome-wide association studyReview030204 cardiovascular system & hematologyGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicinecardiovascular diseaseInternal medicineCholesterylester transfer proteinMendelian randomizationCETPMedicineScavenger receptoreducationEcology Evolution Behavior and Systematicseducation.field_of_studybiologybusiness.industryQPaleontology030104 developmental biologyEndocrinologySpace and Planetary Sciencebiology.proteinlipids (amino acids peptides and proteins)Hepatic lipasehyperalphalipoproteinemiabusinesspolymorphisms
researchProduct

Lipoproteins in atherosclerosis process

2019

Background:Dyslipidaemias is a recognized risk factor for atherosclerosis, however, new evidence brought to light by trials investigating therapies to enhance HDLcholesterol have suggested an increased atherosclerotic risk when HDL-C is high.Results:Several studies highlight the central role in atherosclerotic disease of dysfunctional lipoproteins; oxidised LDL-cholesterol is an important feature, according to “oxidation hypothesis”, of atherosclerotic lesion, however, there is today a growing interest for dysfunctional HDL-cholesterol. The target of our paper is to review the functions of modified and dysfunctional lipoproteins in atherogenesis.Conclusion:Taking into account the central ro…

0301 basic medicineFunctional featuresLipoproteinsAtherogenisiDysfunctional family030204 cardiovascular system & hematologyBioinformaticsBiochemistryOxidised03 medical and health sciences0302 clinical medicineDrug DiscoveryAnimalsHumansMedicineHDL-CRisk factorLipoproteinPharmacologybusiness.industryAnimalOrganic ChemistryAtherosclerotic diseaseAtherosclerosismedicine.diseaseClinical Practice030104 developmental biologyDyslipidemiaAtherosclerosiMolecular Medicinelipids (amino acids peptides and proteins)DysfunctionalbusinessDyslipidemiaHuman
researchProduct